Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.
Domain: Therapeutics & Diagnostics, Other
Therapeutics & Diagnostics, Vaccines
Contact: Avenue de la Roseraie 64
1205 Geneva / GE
P: +41 22 372 38 01

http://www.tolerys.com
Find an actor

Medtech Innovation Event - Sept 4 - Swiss Innovation Park Biel/Bienne04.09.2017

Swiss Medtech, be-advanced and Switzerland Innovation Park Biel/Bienne organise the 3rd matchmaking event solely for...

Welcome To Health Valley

Building on skills honed over the centuries, western Switzerland has become a world leader in biotech.
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn